

Sebastian Berg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5157681/publications.pdf>

Version: 2024-02-01

448
papers

11,471
citations

31976

53
h-index

58581

82
g-index

454
all docs

454
docs citations

454
times ranked

12411
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 287-292.	3.9	3
2	Association between Operative Time and Short-Term Radical Cystectomy Complications. <i>Urologia Internationalis</i> , 2023, 107, 273-279.	1.3	2
3	Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of Vigibase. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 179-181.	1.2	8
4	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	4.2	6
5	High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 62.e1-62.e11.	1.6	1
6	Psychosocial Distress in the Early Recovery Period after Radical Prostatectomy. <i>Urologia Internationalis</i> , 2022, 106, 891-896.	1.3	2
7	Analysis of Surgical Volume in Military Medical Treatment Facilities and Clinical Combat Readiness of US Military Surgeons. <i>JAMA Surgery</i> , 2022, 157, 43.	4.3	33
8	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. <i>JCO Oncology Practice</i> , 2022, 18, e204-e218.	2.9	18
9	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	2.5	2
10	Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade. <i>European Urology</i> , 2022, 81, 323-324.	1.9	4
11	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.. <i>Journal of Clinical Oncology</i> , 2022, 40, 281-281.	1.6	1
12	Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK. <i>JAMA Network Open</i> , 2022, 5, e225740.	5.9	15
13	Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate Specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data. <i>Journal of Urology</i> , 2022, 207, 993-1000.	0.4	7
14	Digital technologies in cancer care: a review from the clinician's perspective. <i>Journal of Comparative Effectiveness Research</i> , 2022, , .	1.4	8
15	Are work relative value units correlated with operative duration of common surgical procedures?. <i>American Journal of Managed Care</i> , 2022, 28, 148-151.	1.1	1
16	Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors and androgen deprivation therapy: a pharmacovigilance study. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	3.9	4
17	Hormone Treatment of Prostate Cancer:. <i>Urologic Clinics of North America</i> , 2022, 49, 309-321.	1.8	1
18	The cost impact of disease progression to metastatic castration-sensitive prostate cancer. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 544-554.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Geographic Variability, Time Trends and Association of Preoperative Magnetic Resonance Imaging with Surgical Outcomes for Elderly United States Men with Prostate Cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Journal of Urology</i> , 2022, 208, 609-617.	0.4	6
20	Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. <i>Annals of Surgical Oncology</i> , 2022, 29, 7206-7215.	1.5	3
21	Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response. <i>Journal of Internal Medicine</i> , 2022, 292, 654-666.	6.0	12
22	Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6555-6555.	1.6	1
23	Risk and predictors of ipilimumab-associated cardiac adverse events among patients treated for melanoma: A national cohort analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14592-e14592.	1.6	0
24	Temporal Trends in the Incidence of Testicular Cancer in the United States over the Past Four Decades. <i>European Urology Oncology</i> , 2021, 4, 834-836.	5.4	5
25	Early continence after ileal neobladder: objective data from inpatient rehabilitation. <i>World Journal of Urology</i> , 2021, 39, 2531-2536.	2.2	5
26	Racial Disparities in Treatment for Rectal Cancer at Minority-Serving Hospitals. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1847-1856.	1.7	22
27	Real-world comparative effectiveness of shockwave lithotripsy versus ureterorenoscopy for the treatment of urinary stones. <i>World Journal of Urology</i> , 2021, 39, 2177-2182.	2.2	1
28	How Do Presenting Symptoms and Outcomes Differ by Race/Ethnicity Among Hospitalized Patients With Coronavirus Disease 2019 Infection? Experience in Massachusetts. <i>Clinical Infectious Diseases</i> , 2021, 73, e4131-e4138.	5.8	30
29	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1644-1650.	2.4	2
30	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 719-726.	6.3	45
31	Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States. <i>Cancer</i> , 2021, 127, 249-256.	4.1	19
32	Access denied: The relationship between patient insurance status and access to high-volume hospitals. <i>Cancer</i> , 2021, 127, 577-585.	4.1	26
33	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 79, 595-604.	1.9	111
34	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. <i>JAMA Dermatology</i> , 2021, 157, 35.	4.1	57
35	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 130.e17-130.e24.	1.6	4
36	The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , 2021, 127, 1387-1394.	4.1	10

#	ARTICLE	IF	CITATIONS
37	The Relationship Between Health Literacy and Nonrecommended Cancer Screening. <i>American Journal of Preventive Medicine</i> , 2021, 60, e69-e72.	3.0	6
38	Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?. <i>Urology</i> , 2021, 147, 199-204.	1.0	9
39	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. <i>European Urology Oncology</i> , 2021, 4, 66-72.	5.4	20
40	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131.	3.1	31
41	Where Is the Value in Ambulatory Versus Inpatient Surgery?. <i>Annals of Surgery</i> , 2021, 273, 909-916.	4.2	51
42	Probability of Prostate Cancer Diagnosis following Negative Systematic and Targeted MRI: Transrectal Ultrasound Fusion Biopsy: A Real-Life Observational Study. <i>Urologia Internationalis</i> , 2021, 105, 446-452.	1.3	0
43	Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. <i>Lung</i> , 2021, 199, 199-211.	3.3	7
44	Temporal trends in the incidence of distant-stage bladder cancer among young individuals. <i>International Journal of Urology</i> , 2021, 28, 704-705.	1.0	2
45	A New Era in Surgical Evaluation—What Is at Stake?. <i>JAMA Surgery</i> , 2021, 156, e206360.	4.3	0
46	Meditative and mind-body practice among patients with genitourinary malignancy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 192.e15-192.e20.	1.6	1
47	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. <i>Oncologist</i> , 2021, 26, e905-e906.	3.7	8
48	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2021, 7, 458.	7.1	177
49	Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures. <i>American Journal of Surgery</i> , 2021, 222, 998-1004.	1.8	7
50	Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position. <i>Cancer</i> , 2021, 127, 2525-2534.	4.1	3
51	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1274-1274.	0.4	0
52	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. <i>Cancer</i> , 2021, 127, 2714-2723.	4.1	12
53	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. <i>Journal of Urology</i> , 2021, 205, 1263-1274.	0.4	10
54	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.7	1

#	ARTICLE	IF	CITATIONS
55	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e654-e665.	2.9	11
56	Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. <i>Eur Urol</i> 2021;79:605-606. <i>European Urology</i> , 2021, 79, 607-608.	1.9	0
57	Value-Based Healthcare in Urology: A Collaborative Review. <i>European Urology</i> , 2021, 79, 571-585.	1.9	27
58	Cardiovascular toxicities associated with abiraterone compared to enzalutamide—A pharmacovigilance study. <i>EClinicalMedicine</i> , 2021, 36, 100887.	7.1	16
59	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 733-741.	1.4	4
60	Association of Hair Loss With Suicidality and Psychological Adverse Events vs Finasteride Use—Reply. <i>JAMA Dermatology</i> , 2021, 157, 738.	4.1	2
61	Reply to Alberto Ingantini, Giorgio Gandaglia, Markus Graefen, Steven Janiau, R. Jeffrey Karnes, and Francesco Montorsi—™s Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>Eur Urol</i> 2021;79:595-604. Time for a Change? Clinically Meaningful Reasons Why We Will	1.9	0
62	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 413-418.	1.3	8
63	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	2.2	3
64	Is the current referral trend a threat to the Military Health System? Perioperative outcomes and costs after colorectal surgery in the Military Health System versus civilian facilities. <i>Surgery</i> , 2021, 170, 67-74.	1.9	7
65	Association of the hospital readmission reduction program with readmission and mortality outcomes after coronary artery bypass graft surgery. <i>Journal of Cardiac Surgery</i> , 2021, 36, 3251-3258.	0.7	1
66	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 436.e1-436.e10.	1.6	4
67	Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. <i>Minerva Urology and Nephrology</i> , 2021, 73, 404-406.	2.5	3
68	ASO Visual Abstract: Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. <i>Annals of Surgical Oncology</i> , 2021, 28, 545.	1.5	1
69	Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 493.e9-493.e15.	1.6	12
70	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021, 39, 1042-1044.	16.8	23
71	Predicting survival after radical prostatectomy: Variation of machine learning performance by race. <i>Prostate</i> , 2021, 81, 1355-1364.	2.3	2
72	Limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population level. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e195-e196.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Measuring What Matters: Patient-Reported Outcome and Experience Measures for Men Undergoing Radical Prostatectomy. <i>European Urology Focus</i> , 2021, 7, 913-915.	3.1	8
74	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103463.	4.4	3
75	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. <i>European Urology Open Science</i> , 2021, 33, 1-10.	0.4	7
76	Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. <i>Investigative and Clinical Urology</i> , 2021, 62, 56.	2.0	4
77	Trends in Surgical Volume in the Military Health System—A Potential Threat to Mission Readiness. <i>Military Medicine</i> , 2021, 186, 646-650.	0.8	24
78	Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems. <i>Prostate</i> , 2021, , .	2.3	5
79	How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer. <i>Urologia Internationalis</i> , 2021, , 1-6.	1.3	0
80	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. <i>European Urology Focus</i> , 2020, 6, 74-80.	3.1	8
81	Contemporary national trends in prostate cancer risk profile at diagnosis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 81-87.	3.9	39
82	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020, 78, 43-59.	1.9	34
83	Suicide Risk Among Patients with Genitourinary Malignancies: Where Do We Stand?. <i>European Urology Focus</i> , 2020, 6, 1145-1146.	3.1	2
84	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 179-183.	3.9	12
85	Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network E2805 Trial Cohort. <i>European Urology</i> , 2020, 77, 277-281.	1.9	18
86	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 135, 44-49.	1.0	5
87	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. <i>Cancer</i> , 2020, 126, 496-505.	4.1	19
88	Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. <i>Journal of Surgical Oncology</i> , 2020, 121, 578-583.	1.7	6
89	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 163-167.	1.3	19
90	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 74.e13-74.e20.	1.6	6

#	ARTICLE	IF	CITATIONS
91	Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 78.e7-78.e13.	1.6	7
92	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 1929-1936.	1.5	3
93	Care Setting as a Modifiable Predictor of Perioperative Cost and Outcomes following Elective Urinary Stone Surgery. <i>Urology Practice</i> , 2020, 7, 259-265.	0.5	3
94	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. <i>World Journal of Urology</i> , 2020, 38, 2227-2236.	2.2	12
95	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 410-418.	3.9	17
96	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 701-710.	1.8	6
97	Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. <i>BMC Surgery</i> , 2020, 20, 235.	1.3	2
98	Changing the Prostate Cancer Detection Paradigm: Clinical Application of European Association of Urology Guidelineâ€‘recommended Magnetic Resonance Imagingâ€‘based Risk Stratification in Men with Suspected Prostate Cancer. <i>European Urology Focus</i> , 2020, 7, 1011-1018.	3.1	3
99	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e9-735.e15.	1.6	2
100	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. <i>Urology</i> , 2020, 145, 197-203.	1.0	1
101	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , 2020, 3, e201839.	5.9	37
102	Prostate cancer management costs vary by disease stage at presentation. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 564-566.	3.9	2
103	Accounting for Readinessâ€‘Integrating Time-Driven Activity-Based Costing (TDABC) into the Military Health System. <i>Military Medicine</i> , 2020, 185, e930-e933.	0.8	5
104	Delayed blood transfusion is associated with mortality following radical cystectomy. <i>Scandinavian Journal of Urology</i> , 2020, 54, 290-296.	1.0	1
105	Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Procedures. <i>Journal of Endourology</i> , 2020, 34, 1248-1254.	2.1	12
106	Inequity in selective referral to high-volume hospitals for genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 582-589.	1.6	6
107	Using Cox Regression to Develop Linear Rank Tests with Zero-Inflated Clustered Data. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2020, 69, 393-411.	1.0	0
108	Institutional Adoption and Apprenticeship of Fusion Targeted Prostate Biopsy: Does Experience Affect the Cancer Detection Rate?. <i>Urologia Internationalis</i> , 2020, 104, 476-482.	1.3	3

#	ARTICLE	IF	CITATIONS
109	Association of Affordable Care Act-related Medicaid expansion with variation in utilization of surgical services. <i>American Journal of Surgery</i> , 2020, 220, 441-447.	1.8	7
110	All for one, one for all: is centralisation the way to go?. <i>BJU International</i> , 2020, 125, 191-192.	2.5	2
111	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. <i>JAMA Network Open</i> , 2020, 3, e1919185.	5.9	18
112	Prostate cancer and kidney transplantation – exclusion or coexistence?. <i>BJU International</i> , 2020, 125, 628-629.	2.5	5
113	Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. <i>BJU International</i> , 2020, 126, 9-10.	2.5	11
114	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e651-e659.	1.9	7
115	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. <i>JAMA Network Open</i> , 2020, 3, e2030072.	5.9	87
116	Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy. <i>Journal of Urology</i> , 2020, 204, 564-569.	0.4	3
117	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5503-5503.	1.6	7
118	Response to Loughlin re: “Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Surgery” by Nguyen et al.. <i>Journal of Endourology</i> , 2020, 34, 1256-1257.	2.1	0
119	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 280-280.	1.6	0
120	Racial/ethnicity differences when endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 351-351.	1.6	0
121	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20224.	3.7	14
122	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 569-569.	0.4	0
123	Impact of Index Surgical Care Setting on Perioperative Outcomes and Cost Following Penile Prosthesis Surgery. <i>Journal of Sexual Medicine</i> , 2019, 16, 1451-1458.	0.6	4
124	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1060-e1068.	1.9	11
125	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. <i>Journal of Oncology Practice</i> , 2019, 15, e547-e559.	2.5	8
126	Development and Validation of a Bedside Risk Assessment for Sustained Prescription Opioid Use After Surgery. <i>JAMA Network Open</i> , 2019, 2, e196673.	5.9	41

#	ARTICLE	IF	CITATIONS
127	EDITORIAL COMMENT. Urology, 2019, 130, 84-85.	1.0	0
128	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
129	Machines in urology: a brief odyssey of the future. BJU International, 2019, 124, 545-546.	2.5	1
130	Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552â€“5 Comparing Apples to Oranges: A Self-fulfilling Prophecy?. European Urology, 2019, 75, e135-e136.	1.9	0
131	Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect realâ€“world practice?. BJU International, 2019, 123, 197-198.	2.5	2
132	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clinical Genitourinary Cancer, 2019, 17, e488-e493.	1.9	11
133	Association of Care at Minority-Serving vs Nonâ€“Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Network Open, 2019, 2, e187633.	5.9	60
134	Trimodal Therapy for Bladder Cancer. JAMA Surgery, 2019, 154, e191637.	4.3	0
135	Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552â€“5. European Urology, 2019, 76, e76-e77.	1.9	0
136	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e194634.	5.9	23
137	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e9-575.e18.	1.6	5
138	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	3.9	8
139	Testosterone replacement therapy is associated with an increased risk of urolithiasis. World Journal of Urology, 2019, 37, 2737-2746.	2.2	6
140	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	1.6	78
141	Re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192â€“8. European Urology Oncology, 2019, 2, 222-223.	5.4	4
142	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	5.4	6
143	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. European Urology Oncology, 2019, 2, 265-273.	5.4	75
144	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	1.9	43

#	ARTICLE	IF	CITATIONS
145	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 125-136.	3.9	53
146	Effect of Medicaid Expansion on Colorectal Cancer Screening Rates. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 97-103.	1.3	48
147	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , 2019, 26, 297-305.	1.5	20
148	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , 2019, 37, 2059-2065.	2.2	40
149	Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. <i>European Urology</i> , 2019, 75, 352-353.	1.9	32
150	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 552-555.	1.9	43
151	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458.	4.1	56
152	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019, 125, 1319-1329.	4.1	20
153	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	1.9	18
154	Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. <i>BJU International</i> , 2019, 123, 385-387.	2.5	6
155	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019, 124, 40-46.	2.5	17
156	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 69-76.	3.1	40
157	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , 2019, 5, 474-481.	3.1	44
158	Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. <i>European Urology Focus</i> , 2019, 5, 77-80.	3.1	43
159	Leveraging the Full Potential of Clinical Registries. <i>European Urology Focus</i> , 2019, 5, 109-110.	3.1	0
160	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019, 201, 735-741.	0.4	31
161	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. <i>Journal of Urology</i> , 2019, 201, 728-734.	0.4	4
162	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 973-978.	0.4	24

#	ARTICLE	IF	CITATIONS
163	Providers'™ inability to estimate health literacy among African American (AA) patients (pts) with early prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, 77-77.	1.6	1
164	Health literacy is a barrier to shared decision making in early prostate cancer (PCA) among African American (AA) men.. Journal of Clinical Oncology, 2019, 37, 84-84.	1.6	2
165	Management Migration™ in United States patients diagnosed with localized prostate cancer from 2010-2015.. Journal of Clinical Oncology, 2019, 37, 11-11.	1.6	0
166	Radical prostatectomy for high-risk prostate cancer Opinion: YES. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 424-427.	1.5	1
167	Clinical and Genomic Characterization of Low™ Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	1.9	72
168	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2018, 200, 573-581.	0.4	31
169	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	1.6	21
170	Adoption of robotic surgery: driven by market competition or a desire to improve patient care?. Lancet Oncology, The, 2018, 19, e66.	10.7	2
171	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns™ Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262™70.. European Urology, 2018, 73, e96-e97.	1.9	0
172	Reassessing the value of high™ volume cancer care in the era of precision medicine. Cancer, 2018, 124, 1319-1321.	4.1	20
173	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.4	70
174	Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU International, 2018, 121, 811-818.	2.5	27
175	The new frontier of prostate biopsy: determining the role of image™ guidance in moving the needle. BJU International, 2018, 121, 4-5.	2.5	0
176	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	1.6	52
177	Evaluation of magnetic resonance imaging and targeted biopsy: The difficulty of finding the right reference standard. Cancer, 2018, 124, 1299-1300.	4.1	0
178	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	1.5	13
179	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. European Urology Focus, 2018, 4, 68-74.	3.1	15
180	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node™ Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score™ Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	3.1	18

#	ARTICLE	IF	CITATIONS
181	Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder. <i>European Urology Focus</i> , 2018, 4, 568-571.	3.1	6
182	Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations. <i>European Urology Focus</i> , 2018, 4, 1002-1004.	3.1	4
183	Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. <i>European Urology Focus</i> , 2018, 4, 775-789.	3.1	68
184	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , 2018, 73, 262-270.	1.9	20
185	Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act. <i>JAMA Oncology</i> , 2018, 4, 128.	7.1	20
186	Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , 2018, 121, 428-436.	2.5	30
187	Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephron-sparing surgery in contemporary North American patients with renal cell cancer. <i>BJU International</i> , 2018, 121, 345-347.	2.5	9
188	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e129-e139.	1.9	17
189	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 225.	7.1	58
190	Secondary data sources for health services research in urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 165-173.	1.6	48
191	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. <i>European Urology</i> , 2018, 73, 452-461.	1.9	46
192	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , 2018, 124, 55-64.	4.1	40
193	The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2018, 199, 424-429.	0.4	33
194	Comparative Effectiveness of Transurethral Resection Techniques in the Inpatient Setting for Benign Prostatic Hyperplasia. <i>Urology Practice</i> , 2018, 5, 377-382.	0.5	1
195	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 78.e13-78.e19.	1.6	16
196	Understanding the impact and challenges of secondary data analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 163-164.	1.6	10
197	State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. <i>Urology</i> , 2018, 112, 56-65.	1.0	7
198	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e100-e101.	1.9	1

#	ARTICLE	IF	CITATIONS
199	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 226-234.	1.9	14
200	Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. <i>Journal of Urology</i> , 2018, 199, 89-97.	0.4	34
201	Prostate Cancer Screening in Early Medicaid Expansion States. <i>Journal of Urology</i> , 2018, 199, 81-88.	0.4	28
202	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , 2018, 73, 445-451.	1.9	43
203	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382.	1.9	62
204	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. <i>JAMA Oncology</i> , 2018, 4, 1619.	7.1	0
205	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 400.e15-400.e22.	1.6	1
206	Use of Preventive Health Services Among Cancer Survivors in the U.S.. <i>American Journal of Preventive Medicine</i> , 2018, 55, 830-838.	3.0	11
207	Contemporary trends in the utilisation of radical prostatectomy. <i>BJU International</i> , 2018, 122, 726-728.	2.5	7
208	Costs variations for percutaneous nephrolithotomy in the U.S. from 2003â€“2015: A contemporary analysis of an all-payer discharge database. <i>Canadian Urological Association Journal</i> , 2018, 12, .	0.6	6
209	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. <i>Canadian Urological Association Journal</i> , 2018, 13, 32-37.	0.6	2
210	Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 469.e1-469.e11.	1.6	37
211	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018, 36, 1767-1774.	2.2	12
212	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1439-1445.	1.0	32
213	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. <i>European Urology Oncology</i> , 2018, 1, 83-90.	5.4	59
214	Impact of sexual orientation on contemporary rates of prostate cancer screening.. <i>Journal of Clinical Oncology</i> , 2018, 36, 122-122.	1.6	0
215	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. <i>World Journal of Urology</i> , 2017, 35, 199-206.	2.2	19
216	The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. <i>European Urology</i> , 2017, 72, 14-19.	1.9	128

#	ARTICLE	IF	CITATIONS
217	The Rise of Robotic Surgery in the New Millennium. <i>Journal of Urology</i> , 2017, 197, S213-S215.	0.4	23
218	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 563-569.e3.	1.9	7
219	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 852-860.	1.6	104
220	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. <i>Current Urology Reports</i> , 2017, 18, 15.	2.2	49
221	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. <i>Urology</i> , 2017, 103, 91-98.	1.0	27
222	Could lead-time bias explain the apparent benefits of early salvage radiotherapy?. <i>Nature Reviews Urology</i> , 2017, 14, 193-194.	3.8	11
223	Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 460.e9-460.e20.	1.6	22
224	Challenging Residual Contamination of Instruments for Robotic Surgery in Japan. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 501-502.	1.8	2
225	Risk Assessment in Small Renal Masses. <i>Urologic Clinics of North America</i> , 2017, 44, 189-202.	1.8	6
226	Do micropapillary patients benefit from chemotherapy?. <i>BJU International</i> , 2017, 119, 656-658.	2.5	5
227	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017, 72, 483-487.	1.9	110
228	Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. <i>Cancer</i> , 2017, 123, 3241-3252.	4.1	89
229	Weighing the evidence from surgical trials. <i>BJU International</i> , 2017, 119, 659-660.	2.5	10
230	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2017, 71, 714-718.	1.9	40
231	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e25-542.e32.	1.6	6
232	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. <i>Journal of Urology</i> , 2017, 198, 1061-1068.	0.4	31
233	Secondary data analysis. <i>Current Opinion in Urology</i> , 2017, 27, 354-359.	1.8	44
234	Accountable care organizations and the use of cancer screening. <i>Preventive Medicine</i> , 2017, 101, 15-17.	3.4	18

#	ARTICLE	IF	CITATIONS
235	Complications After Metastasectomy for Renal Cell Carcinoma—A Population-based Assessment. <i>European Urology</i> , 2017, 72, 171-174.	1.9	44
236	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 338-343.	0.8	9
237	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 1206-1207.	0.4	0
238	Assessing robot-assisted laparoscopic prostatectomy. <i>Lancet, The</i> , 2017, 389, 799.	13.7	5
239	The association of hypoalbuminemia with early perioperative outcomes — A comprehensive assessment across 16 major procedures. <i>American Journal of Surgery</i> , 2017, 214, 871-883.	1.8	42
240	The Effect of Physician Specialty Obtaining Access for Percutaneous Nephrolithotomy on Perioperative Costs and Outcomes. <i>Journal of Endourology</i> , 2017, 31, 1152-1156.	2.1	14
241	Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 588-597.	1.5	46
242	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. <i>Journal of Urology</i> , 2017, 198, 1295-1300.	0.4	10
243	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , 2017, 123, 4346-4355.	4.1	138
244	Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e955-e968.	1.9	17
245	Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. <i>International Journal of Urology</i> , 2017, 24, 743-748.	1.0	34
246	Emergency Department Utilization in Patients With Neurogenic Bladder: Contemporary Burden and National Trends in Prevalence, Inpatient Admission, and Associated Charges, 2006-2011. <i>Urology</i> , 2017, 109, 74-81.	1.0	0
247	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 904-911.	0.8	6
248	Immortal-time bias: a crucial yet overlooked confounder in urological research. <i>BJU International</i> , 2017, 120, 455-455.	2.5	1
249	Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? <i>Eur Urol</i> 2017;72:488-9. <i>European Urology</i> , 2017, 72, 489-491.	1.9	1
250	Efficient Computation of Reduced Regression Models. <i>American Statistician</i> , 2017, 71, 171-176.	1.6	0
251	Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis. <i>Acta Neuropathologica Communications</i> , 2017, 5, 40.	5.2	13
252	Adoption of Technology and Its Impact on Nephrectomy Outcomes, a U.S. Population-Based Analysis (2008-2012). <i>Journal of Endourology</i> , 2017, 31, 91-99.	2.1	15

#	ARTICLE	IF	CITATIONS
253	Does Low-value Care Affect Urologists?. <i>European Urology</i> , 2017, 71, 304-305.	1.9	2
254	Postoperative sepsis prediction in patients undergoing major cancer surgery. <i>Journal of Surgical Research</i> , 2017, 209, 60-69.	1.6	15
255	Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer. <i>European Urology</i> , 2017, 71, 511-514.	1.9	22
256	Reply to C. Buttigliero et al and B. Biswas et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1266-1267.	1.6	0
257	Minimally invasive vs open nephrectomy in the modern era: does approach matter?. <i>World Journal of Urology</i> , 2017, 35, 1557-1568.	2.2	36
258	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 305-305.	1.6	63
259	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 332-332.	1.6	1
260	National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 50-50.	1.6	0
261	The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 19-19.	1.6	1
262	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. <i>Journal of Clinical Oncology</i> , 2017, 35, 18-18.	1.6	0
263	Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 164-164.	1.6	1
264	Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review.. <i>Journal of Clinical Oncology</i> , 2017, 35, 150-150.	1.6	1
265	Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 529-529.	1.6	1
266	Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 331-331.	1.6	0
267	Adverse effects of androgen deprivation therapy on cognitive impairment for men with prostate cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16506-e16506.	1.6	0
268	Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5080-5080.	1.6	1
269	Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16001-e16001.	1.6	0
270	Pneumonia after Major Cancer Surgery: Temporal Trends and Patterns of Care. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	1.6	12

#	ARTICLE	IF	CITATIONS
271	Assessment of energy density usage during 180W lithium triborate laser photoselective vaporization of the prostate for benign prostatic hyperplasia. Is there an optimum amount of kilojoules per gram of prostate?. <i>BJU International</i> , 2016, 118, 633-640.	2.5	28
272	Treatment patterns, testicular loss and disparities in inpatient surgical management of testicular torsion in boys: a population-based study 1998-2010. <i>BJU International</i> , 2016, 118, 969-979.	2.5	7
273	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016, 118, 279-285.	2.5	14
274	Suicide and accidental deaths among patients with non-metastatic prostate cancer. <i>BJU International</i> , 2016, 118, 286-297.	2.5	39
275	Association of Androgen Deprivation Therapy With Alzheimer's Disease: Unmeasured Confounders. <i>Journal of Clinical Oncology</i> , 2016, 34, 2801-2803.	1.6	6
276	Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. <i>BJU International</i> , 2016, 118, 221-229.	2.5	22
277	Data on Medicare eligibility and cancer screening utilization. <i>Data in Brief</i> , 2016, 7, 679-681.	1.0	4
278	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. <i>European Urology Focus</i> , 2016, 2, 3-9.	3.1	7
279	Asian Americans and prostate cancer: A nationwide population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 233.e7-233.e15.	1.6	34
280	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. <i>Eur Urol</i> 2015;68:756-765. <i>European Urology</i> , 2016, 69, e129.	1.9	0
281	Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort. <i>Urology</i> , 2016, 90, 69-75.	1.0	18
282	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. <i>Urology</i> , 2016, 94, 70-76.	1.0	10
283	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1905-1912.	1.6	121
284	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 293.e1-293.e10.	1.6	43
285	Determinants of cancer screening in Asian-Americans. <i>Cancer Causes and Control</i> , 2016, 27, 989-998.	1.8	33
286	Wound dehiscence in a sample of 1776 cystectomies: identification of predictors and implications for outcomes. <i>BJU International</i> , 2016, 117, E95-E101.	2.5	23
287	Accurately determining patients who underwent robot-assisted surgery: limitations of administrative databases. <i>BJU International</i> , 2016, 118, 346-348.	2.5	10
288	Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 305-311.	1.0	10

#	ARTICLE	IF	CITATIONS
289	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016, 15, 695-700.	0.5	13
290	Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. <i>Journal of Endourology</i> , 2016, 30, 1291-1295.	2.1	4
291	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016, 122, 3371-3377.	4.1	27
292	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 421-428.	4.9	10
293	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3267-3275.	1.6	185
294	Observational Studies to Contextualize Surgical Trials. <i>European Urology</i> , 2016, 70, 231-232.	1.9	2
295	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. <i>Preventive Medicine</i> , 2016, 89, 140-145.	3.4	63
296	Re: Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. <i>European Urology</i> , 2016, 69, 963-964.	1.9	2
297	S&T-46 COMPARISON OF GLEASON SCORE MISCLASSIFICATION BETWEEN TRANSRECTAL ULTRASOUND AND MAGNETIC RESONANCE IMAGING FUSION GUIDED PROSTATE BIOPSIES AND SYSTEMATIC BIOPSIES. A PROSPECTIVE ANALYSIS ACCORDING TO FINAL HISTOPATHOLOGY AFTER PROSTATECTOMY.. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
298	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2016, 196, 1090-1095.	0.4	42
299	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536.	1.6	70
300	New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (<sc>COX</sc>) blockers in erectile dysfunction. <i>BJU International</i> , 2016, 117, 385-386.	2.5	2
301	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. <i>JAMA Oncology</i> , 2016, 2, 543.	7.1	5
302	Targeted Cancer Screening After Solid-Organ Transplantation. <i>JAMA Oncology</i> , 2016, 2, 470.	7.1	2
303	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 57.e15-57.e22.	1.6	17
304	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. <i>Journal of Urology</i> , 2016, 195, 913-918.	0.4	32
305	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. <i>European Urology</i> , 2016, 70, 837-845.	1.9	178
306	Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations. <i>JAMA Internal Medicine</i> , 2016, 176, 546.	5.1	32

#	ARTICLE	IF	CITATIONS
307	Adverse Event Rates, Timing of Complications, and the Impact of Specialty on Outcomes Following Adrenal Surgery: An Analysis of 30-Day Outcome Data From the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). <i>Urology</i> , 2016, 90, 62-68.	1.0	13
308	Editorial Comment. <i>Urology</i> , 2016, 87, 86-87.	1.0	0
309	The impact of Medicare eligibility on cancer screening behaviors. <i>Preventive Medicine</i> , 2016, 85, 47-52.	3.4	19
310	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. <i>Journal of Urology</i> , 2016, 195, 399-405.	0.4	8
311	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with $\geq 50\%$ Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016, 87, 125-132.	1.0	16
312	Causes of hospital readmissions after urologic cancer surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 236.e1-236.e11.	1.6	36
313	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. <i>JAMA Oncology</i> , 2016, 2, 500.	7.1	94
314	Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. <i>European Urology</i> , 2016, 69, 92-93.	1.9	0
315	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016, 118, 95-101.	2.5	45
316	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 85.	7.1	86
317	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016, 117, E20-8.	2.5	22
318	A Surveillance, Epidemiology and End Results (<sc>SEER</sc>) database malfunction: perceptions, pitfalls and verities. <i>BJU International</i> , 2016, 117, 551-552.	2.5	31
319	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4524-4524.	1.6	6
320	The impact of histological variants on bladder cancer survival: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 458-458.	1.6	1
321	Understanding the roles of randomized trials for robotic prostatectomy. <i>Annals of Translational Medicine</i> , 2016, 4, 467-467.	1.7	1
322	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 54-54.	1.6	0
323	Open Versus Robotic Radical Prostatectomy in Obese Men. <i>Current Urology</i> , 2015, 8, 156-161.	0.6	12
324	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1351-1358.	4.9	17

#	ARTICLE	IF	CITATIONS
325	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1131-1138.	4.9	37
326	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 61-68.	4.9	72
327	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures. <i>Annals of Surgery</i> , 2015, 262, 955-964.	4.2	101
328	An evaluation of the "weekend effect"™ in patients admitted with metastatic prostate cancer. <i>BJU International</i> , 2015, 116, 911-919.	2.5	8
329	How can we improve surgical outcomes?. <i>BJU International</i> , 2015, 116, 835-836.	2.5	0
330	Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. <i>BJU International</i> , 2015, 116, 703-712.	2.5	11
331	Predictors of early continence following robot-assisted radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2015, 9, 93.	0.6	47
332	Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experience. <i>Canadian Urological Association Journal</i> , 2015, 9, 434.	0.6	1
333	Factors predicting prolonged operative time for individual surgical steps of robot-assisted radical prostatectomy (RARP): A single surgeon's™ experience. <i>Canadian Urological Association Journal</i> , 2015, 9, 417.	0.6	16
334	Inpatients hypospadias care: Trends and outcomes from the American nationwide inpatient sample. <i>Korean Journal of Urology</i> , 2015, 56, 594.	1.2	2
335	NATIONAL RATES AND RISK FACTORS FOR STENT FAILURE IN PATIENTS WITH OBSTRUCTED, INFECTED UPPER TRACT STONES. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.	0.6	7
336	Impact of smoking on perioperative outcomes after major surgery. <i>American Journal of Surgery</i> , 2015, 210, 221-229.e6.	1.8	69
337	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. <i>American Journal of Medicine</i> , 2015, 128, 609-616.	1.5	21
338	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. <i>European Urology</i> , 2015, 68, 32-39.	1.9	43
339	Urolithiasis and Urinary Tract Infection Among Patients With Inflammatory Bowel Disease: A Review of US Emergency Department Visits between 2006 and 2009. <i>Urology</i> , 2015, 85, 764-770.	1.0	18
340	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e123-e130.	1.9	35
341	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 257-276.	4.4	37
342	Reply. <i>Urology</i> , 2015, 85, 349-350.	1.0	0

#	ARTICLE	IF	CITATIONS
343	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	1.0	21
344	Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. <i>Journal of Urology</i> , 2015, 193, 820-825.	0.4	40
345	Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection: Data from the nationwide emergency department sample, 2006 to 2011. <i>Journal of Pediatric Urology</i> , 2015, 11, 246.e1-246.e8.	1.1	44
346	Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia Using the 180 Watt System: Multicenter Study of the Impact of Prostate Size on Safety and Outcomes. <i>Journal of Urology</i> , 2015, 194, 462-469.	0.4	50
347	Patient Characteristics and Perioperative Outcomes of Female Urethral Diverticulectomy: Analysis of a Multi-Institutional Prospective Database. <i>Urology</i> , 2015, 86, 712-715.	1.0	8
348	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 251-263.	4.4	8
349	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 330.e19-330.e25.	1.6	13
350	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 525-530.e3.	1.9	23
351	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. <i>Journal of Endourology</i> , 2015, 29, 1052-1058.	2.1	23
352	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>European Urology</i> , 2015, 68, 949-956.	1.9	50
353	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv054-djv054.	6.3	63
354	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. <i>Urology</i> , 2015, 85, 937-941.	1.0	21
355	Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>Urology</i> , 2015, 85, 890-895.	1.0	11
356	Effect of Preoperative Angina Pectoris on Cardiac Outcomes in Patients With Previous Myocardial Infarction Undergoing Major Noncardiac Surgery (Data from ACS-NSQIP). <i>American Journal of Cardiology</i> , 2015, 115, 1080-1084.	1.6	16
357	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 228-237.	4.4	111
358	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. <i>World Journal of Urology</i> , 2015, 33, 2107-2113.	2.2	16
359	An evaluation of the timing of surgical complications following nephrectomy: data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). <i>World Journal of Urology</i> , 2015, 33, 2031-2038.	2.2	26
360	Novel biomarkers of acute kidney injury: Evaluation and evidence in urologic surgery. <i>World Journal of Nephrology</i> , 2015, 4, 160.	2.0	21

#	ARTICLE	IF	CITATIONS
361	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. <i>European Urology</i> , 2015, 68, 756-765.	1.9	57
362	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. <i>Journal of Surgical Education</i> , 2015, 72, 1018-1025.	2.5	36
363	Complications After Surgery for Stress Urinary Incontinence. <i>JAMA Surgery</i> , 2015, 150, 1175.	4.3	2
364	Rates of Kidney Transplantation From Living and Deceased Donors for Blacks and Whites in the United States, 1998 to 2011. <i>JAMA Internal Medicine</i> , 2015, 175, 1716.	5.1	11
365	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 503.e7-503.e15.	1.6	9
366	Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 828-835.	0.8	40
367	The influence of physician recommendation on prostate-specific antigen screening. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 424.e1-424.e7.	1.6	28
368	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 504.e9-504.e17.	1.6	21
369	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2077.	7.4	105
370	Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. <i>BJU International</i> , 2015, 116, 358-365.	2.5	66
371	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 17.e9-17.e18.	1.6	24
372	Income inequality and treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e7-18.e13.	1.6	53
373	Sepsis after major cancer surgery. <i>Journal of Surgical Research</i> , 2015, 193, 788-794.	1.6	28
374	Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. <i>European Urology</i> , 2015, 67, 3-6.	1.9	136
375	The Controversy That Will Not Go Away. <i>European Urology</i> , 2015, 67, 439-440.	1.9	3
376	Diagnosis and Staging of Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 205-218.	2.2	62
377	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. <i>Canadian Urological Association Journal</i> , 2015, 9, 207.	0.6	13
378	Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 89-89.	1.6	0

#	ARTICLE	IF	CITATIONS
379	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15583-e15583.	1.6	0
380	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17528-e17528.	1.6	0
381	Robot-assisted versus laparoscopic nephroureterectomy for uppertract urothelial cancer: A population-based assessment of costs and perioperative outcomes. <i>Canadian Urological Association Journal</i> , 2014, 8, 695.	0.6	42
382	Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study. <i>Canadian Urological Association Journal</i> , 2014, 8, 419.	0.6	4
383	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. <i>Canadian Urological Association Journal</i> , 2014, 8, 681.	0.6	51
384	Robotic nephrolithotomy and pyelolithotomy with utilization of the robotic ultrasound probe. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 125-126.	1.5	21
385	Utilization and perioperative outcomes of robotic vaginal vault suspension compared to abdominal or vaginal approaches for pelvic organ prolapse. <i>Canadian Urological Association Journal</i> , 2014, 8, 100.	0.6	12
386	Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2014, 8, 148.	0.6	42
387	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. <i>Canadian Urological Association Journal</i> , 2014, 8, 75.	0.6	11
388	Is there any evidence of a "July effect" in patients undergoing major cancer surgery?. <i>Canadian Journal of Surgery</i> , 2014, 57, 82-88.	1.2	30
389	Contemporary incidence and mortality rates of kidney cancer in the United States. <i>Canadian Urological Association Journal</i> , 2014, 8, 247.	0.6	78
390	Venous Thromboembolism After Major Cancer Surgery. <i>JAMA Surgery</i> , 2014, 149, 43.	4.3	158
391	Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. <i>Cancer</i> , 2014, 120, 1532-1539.	4.1	204
392	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1259-1266.	1.6	50
393	Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections. <i>JAMA Surgery</i> , 2014, 149, 1039.	4.3	109
394	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. <i>Journal of Clinical Oncology</i> , 2014, 32, 2025-2030.	1.6	112
395	Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening. <i>JAMA Internal Medicine</i> , 2014, 174, 1839.	5.1	33
396	Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population. <i>JAMA Internal Medicine</i> , 2014, 174, 1468.	5.1	1

#	ARTICLE	IF	CITATIONS
397	The impact of resident involvement in minimally-invasive urologic oncology procedures. Canadian Urological Association Journal, 2014, 8, 334.	0.6	46
398	Emergency Department Visits in the United States for Upper Urinary Tract Stones: Trends in Hospitalization and Charges. Journal of Urology, 2014, 191, 90-96.	0.4	88
399	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. European Urology, 2014, 66, 569-576.	1.9	205
400	Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma. European Urology, 2014, 65, 1014-1015.	1.9	5
401	The impact of androgenâ€deprivation therapy (<scp>ADT</scp>) on the risk of cardiovascular (<scp>CV</scp>) events in patients with nonâ€metastatic prostate cancer: a populationâ€based study. BJU International, 2014, 114, E82-E89.	2.5	77
402	Minimally Invasive vs Open Pyeloplasty in Children: The Differential Effect of Procedure Volume on Operative Outcomes. Urology, 2014, 84, 180-184.	1.0	24
403	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. European Urology, 2014, 66, 1125-1132.	1.9	29
404	Pediatric Nephrectomy: Incidence, Indications and Use of Minimally Invasive Techniques. Journal of Urology, 2014, 191, 764-770.	0.4	17
405	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. European Urology, 2014, 66, 561-568.	1.9	70
406	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competingâ€risks analysis. BJU International, 2014, 114, E62-E69.	2.5	20
407	Predicting Other-cause Mortality: The Minimalistic Approach. European Urology, 2014, 66, 1010-1011.	1.9	0
408	Mental health outcomes in elderly men with prostate cancer1Equal contribution.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	1.6	59
409	Models of Assessment of Comparative Outcomes of Robot-Assisted Surgery. Urologic Clinics of North America, 2014, 41, 597-606.	1.8	6
410	Accuracy of Transrectal Ultrasonography to Evaluate Pathologic Prostate Weight: Correlation With Various Prostate Size Groups. Urology, 2014, 84, 169-174.	1.0	9
411	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	1.0	86
412	Difluoro-dioxolo-benzoimidazol-benzamides As Potent Inhibitors of CK1Î and Îµ with Nanomolar Inhibitory Activity on Cancer Cell Proliferation. Journal of Medicinal Chemistry, 2014, 57, 7933-7946.	6.4	29
413	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. Journal of Urology, 2014, 191, 1678-1684.	0.4	19
414	Racial Disparities in Prostate Cancerâ€Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	1.9	46

#	ARTICLE	IF	CITATIONS
415	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	1.0	17
416	A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2014, 90, 49-57.	4.4	3
417	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 27.e7-27.e13.	1.6	24
418	Population-based Comparative Effectiveness of Salvage Radical Prostatectomy vs Cryotherapy. Urology, 2014, 83, 653-657.	1.0	11
419	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	1.9	97
420	Practice Patterns and Outcomes of Open and Minimally Invasive Partial Nephrectomy Since the Introduction of Robotic Partial Nephrectomy: Results from the Nationwide Inpatient Sample. Journal of Urology, 2014, 191, 907-913.	0.4	197
421	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. European Urology, 2014, 66, 156-163.	1.9	156
422	Editorial Comment. Urology, 2014, 83, 630-631.	1.0	0
423	Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 303-308.	1.6	22
424	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e1-46.e7.	1.6	25
425	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 2014, 5, 352-358.	1.0	21
426	Perceptions of Radiation Oncologists and Urologists on Sources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 277-283.	0.8	3
427	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1285-1291.	1.6	81
428	Laparoscopic Radical Nephrectomy vs Laparoscopic or Open Partial Nephrectomy for T1 Renal Cell Carcinoma: Comparison of Complication Rates in Elderly Patients During the Initial Phase of Adoption. Urology, 2014, 83, 1285-1293.	1.0	26
429	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 29.e13-29.e20.	1.6	34
430	Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report.. Journal of Clinical Oncology, 2014, 32, 334-334.	1.6	1
431	Association of partial nephrectomy and presence of robotic surgery for kidney cancer in the United States.. Journal of Clinical Oncology, 2014, 32, 484-484.	1.6	0
432	Effect of Nodal Metastases on Cancer-specific Mortality After Cyto-reductive Nephrectomy. Annals of Surgical Oncology, 2013, 20, 2096-2102.	1.5	18

#	ARTICLE	IF	CITATIONS
433	Disparities in Access to Hospitals with Robotic Surgery for Patients with Prostate Cancer Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , 2013, 189, 514-520.	0.4	57
434	Discharge patterns after radical prostatectomy in the United States of America. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1022-1032.	1.6	22
435	A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. <i>European Urology</i> , 2013, 64, 786-798.	1.9	172
436	Does partial nephrectomy at an academic institution result in better outcomes?. <i>World Journal of Urology</i> , 2012, 30, 505-510.	2.2	7
437	Robot-assisted urological surgery: Current status and future perspectives. <i>Arab Journal of Urology Arab Association of Urology</i> , 2012, 10, 17-22.	1.5	5
438	Morbidity and mortality of radical prostatectomy differs by insurance status. <i>Cancer</i> , 2012, 118, 1803-1810.	4.1	41
439	Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. <i>Cancer</i> , 2012, 118, 1894-1900.	4.1	25
440	Disparities in access to care at high-volume institutions for urologic oncologic procedures. <i>Cancer</i> , 2012, 118, 4421-4426.	4.1	65
441	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. <i>Cancer</i> , 2012, 118, 4991-4998.	4.1	17
442	Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. <i>European Urology</i> , 2012, 61, 679-685.	1.9	345
443	Open radical prostatectomy in the elderly: a case for concern?. <i>BJU International</i> , 2012, 109, 1335-1340.	2.5	14
444	Radical Prostatectomy at Academic Versus Nonacademic Institutions: A Population Based Analysis. <i>Journal of Urology</i> , 2011, 186, 1849-1854.	0.4	33
445	Robot-Assisted Partial Nephrectomy Using Robotically Applied Bulldog Clamps for Hilar Clamping: Initial Series, Technique, and Outcomes. <i>Videourology (New Rochelle, N Y)</i> , 2011, 25, .	0.1	1
446	Urethrovesical Anastomosis Using Barbed Suture During Robot-Assisted Radical Prostatectomy. <i>Videourology (New Rochelle, N Y)</i> , 2011, 25, .	0.1	1
447	Robot-Assisted Partial Nephrectomy. <i>Videourology (New Rochelle, N Y)</i> , 2011, 25, .	0.1	0
448	Trends in Launch Prices and Price Increases for New Medicines for Urological Cancers. <i>Journal of Urology</i> , 0, , .	0.4	0